The latest price target for Pyxis Oncology (NASDAQ:PYXS) was reported by Wedbush on May 5, 2026. The analyst firm set a price target for $6.00 expecting PYXS to rise to within 12 months (a possible 203.03% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Pyxis Oncology (NASDAQ:PYXS) was provided by Wedbush, and Pyxis Oncology initiated their outperform rating.

There is no last upgrade for Pyxis Oncology

The last downgrade for Pyxis Oncology Inc happened on November 21, 2024 when William Blair changed their price target from N/A to N/A for Pyxis Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pyxis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pyxis Oncology was filed on May 5, 2026 so you should expect the next rating to be made available sometime around May 5, 2027.

While ratings are subjective and will change, the latest Pyxis Oncology (PYXS) rating was a initiated with a price target of $0.00 to $6.00. The current price Pyxis Oncology (PYXS) is trading at is $1.98, which is within the analyst’s predicted range.